10-KPeriod: FY2025

ALTRIA GROUP, INC. Annual Report, Year Ended Dec 31, 2025

Filed February 25, 2026For Securities:MO

Summary

Altria Group, Inc. reported net earnings of $6.9 billion for the fiscal year ending December 31, 2025, a decrease from the prior year. This decline was primarily attributed to a significant gain on the sale of IQOS commercialization rights in the previous year, alongside lower operating income. Despite this, adjusted net earnings saw a modest increase of 2.4% to $9.1 billion, driven by higher operating companies income (OCI) and a lower adjusted tax rate. The company continues its strategic shift "MovingBeyondSmokingTM," focusing on transitioning adult smokers to a smoke-free future and exploring new growth avenues. However, challenges persist, notably the substantial non-cash impairments of $1.16 billion recorded against goodwill and intangible assets within the e-vapor reporting unit due to ongoing regulatory uncertainties and the impact of illicit flavored disposable e-vapor products. The company demonstrated a continued commitment to shareholder returns through dividends and share repurchases, increasing its quarterly dividend rate by 3.9% and maintaining a progressive dividend growth target. While the core smokeable products segment experienced a revenue decline due to lower shipment volumes, pricing actions helped to partially offset this. The oral tobacco products segment showed revenue growth, driven by pricing, though volume/mix declined. The company faces ongoing regulatory scrutiny and market shifts, which it is navigating through its strategic "Optimize & Accelerate" initiative aimed at enhancing efficiency and effectiveness.

Financial Statements
Beta

Key Highlights

  • 1Altria reported net earnings of $6.9 billion for FY2025, down from $11.3 billion in FY2024, largely due to prior-year gains from the IQOS sale.
  • 2Adjusted net earnings increased by 2.4% to $9.1 billion, with adjusted diluted EPS growing 4.4% to $5.42, indicating underlying operational improvement.
  • 3Significant non-cash impairments totaling $1.16 billion were recorded against the e-vapor reporting unit's goodwill and definite-lived intangible assets, reflecting challenges in the e-vapor market, particularly from illicit products.
  • 4The smokeable products segment saw a 3.4% net revenue decline to $20.5 billion, primarily due to a 10.0% decrease in cigarette shipment volume, partially mitigated by pricing increases.
  • 5The oral tobacco products segment experienced a slight net revenue increase of 0.9% to $2.8 billion, driven by higher pricing, although shipment volume/mix decreased.
  • 6Altria repurchased $1 billion of its stock under its share repurchase program and increased its quarterly dividend by 3.9%, reaffirming its commitment to shareholder returns.
  • 7The company's "Optimize & Accelerate" initiative is on track, with ongoing efforts to achieve cumulative savings of at least $600 million by the end of 2029.

Frequently Asked Questions

Altria reported a net earnings decrease of 38.3% to $6.9 billion in 2025 from $11.3 billion in 2024. This was primarily due to a significant gain from the sale of IQOS System commercialization rights in 2024. However, adjusted net earnings increased by 2.4% to $9.1 billion, and adjusted diluted EPS rose by 4.4% to $5.42, indicating underlying operational improvements.

Altria recorded substantial non-cash impairments totaling $1.16 billion in 2025 for its e-vapor reporting unit's goodwill and definite-lived intangible assets. This was mainly due to the impact of illicit flavored disposable e-vapor products, protracted ineffective enforcement against these products, and regulatory uncertainties, including the ITC exclusion order and cease-and-desist orders against NJOY ACE.

The company's smokeable products segment experienced a 3.4% net revenue decline, driven by a 10.0% drop in cigarette shipment volume. Altria is attempting to mitigate this through pricing actions, which contributed to higher pricing for its premium cigarette brands and cigars, helping to offset some of the volume loss.

Altria's strategy focuses on transitioning adult smokers to smoke-free products, competing for smoke-free nicotine consumers, and exploring growth opportunities beyond the U.S. and beyond nicotine. This includes developing its oral nicotine pouch brand 'on!' and its e-vapor brand NJOY. The company also has a joint venture for heated tobacco stick products. However, progress in the smoke-free category is being reassessed due to market disruptions from illicit e-vapor products.

Altria demonstrates a commitment to shareholder returns by increasing its quarterly dividend by 3.9% and maintaining a progressive dividend growth target. The company also repurchased $1 billion in common stock during 2025 under its authorized share repurchase program. The 'Optimize & Accelerate' initiative aims to generate cost savings which are planned to be reinvested in the business to support its long-term vision.